Target and tissue selectivity of PROTAC degraders
The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
Targeted protein degradation (TPD) strategies have revolutionized how scientists tackle challenging protein targets deemed undruggable with traditional small molecule inhibitors. Many promising campaigns to inhibit proteins have failed due to factors surrounding inhibition selectivity and targeting of compounds to specific tissues and cell types. One of the major improvements that PROTAC (proteolysis targeting chimera) and molecular glue technology can exert is highly selective control of target inhibition. Multiple studies have shown that PROTACs can gain selectivity for their protein targets beyond that of their parent ligands via optimization of linker length and stabilization of ternary complexes. Due to the bifunctional nature of PROTACs, the tissue selective nature of E3 ligases can be exploited to uncover novel targeting mechanisms. In this review, we provide critical analysis of the recent progress towards making selective PROTAC molecules and new PROTAC technologies that will continue to push the boundaries of achieving selectivity. These efforts have wide implications in the future of treating disease as they will broaden the possible targets that can be addressed by small molecules, like undruggable proteins or broadly active targets that would benefit from degradation in specific tissue types.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, PROTAC technology leverages E3 ligases, which may be selectively expressed in certain tissues, to drive the targeted degradation of specific targets,520 offering significant opportunities for AD treatment.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [520]
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Photoremovable Protecting Groups in Chemistry and Biology: Reaction Mechanisms and Efficacy
Klán, P., Šolomek, T., Bochet, C. G., Blanc, A., Givens, R., Rubina, M., Popik, V., Kostikov, A., & Wirz, J. (2013) · Chemical Reviews · doi:10.1021/cr300177k · Cited by 1,827
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Research works printed but not linked: 1
- Chomez, 2001, Cancer Res., 61, 5544
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
Chemistries of bifunctional PROTAC degraders
Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313
Li, X., Chen, M., Chen, X., He, X., Li, X., Wei, H., Tan, Y., Min, J., Azam, T., Xue, M., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae379 · Cited by 198
Self-citationNew-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Wang, C., Zhang, Y., Chen, W., Wu, Y., & Xing, D. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02024-9 · Cited by 188
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery
Guedeney, N., Cornu, M., Schwalen, F., Kieffer, C., & Voisin-Chiret, A. S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103395 · Cited by 162
Self-Assembled Nano-PROTAC Enables Near-Infrared Photodynamic Proteolysis for Cancer Therapy
Wang, W., Zhu, C., Zhang, B., Feng, Y., Zhang, Y., & Li, J. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c04109 · Cited by 154
Characteristic roadmap of linker governs the rational design of PROTACs
Dong, Y., Ma, T., Xu, T., Feng, Z., Li, Y., Song, L., Yao, X., Ashby, C. R., & Hao, G.-F. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.007 · Cited by 146
Zhang, Y., Jiang, H., Dong, M., Min, J., He, X., Tan, Y., Liu, F., Chen, M., Chen, X. '., Yin, Q., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114180 · Cited by 132
Self-citationWu, Y., Chang, X., Yang, G., Chen, L., Wu, Q., Gao, J., Tian, R., Mu, W., Gooding, J. J., Chen, X., et al. (2023) · Advanced Materials · doi:10.1002/adma.202210787 · Cited by 140
Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders
Lu, P., Cheng, Y., Xue, L., Ren, X., Xu, X., Chen, C., Cao, L., Li, J., Wu, Q., Sun, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.015 · Cited by 123
Zhou, Y., Li, C., Chen, X., Zhao, Y., Liao, Y., Huang, P., Wu, W., Nieto, N. S., Li, L., & Tang, W. (2024) · Nature Communications · doi:10.1038/s41467-024-52685-9 · Cited by 106
Peng, X., Hu, Z., Zeng, L., Zhang, M., Xu, C., Lu, B., Tao, C., Chen, W., Hou, W., Cheng, K., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.09.003 · Cited by 91
PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer
Rutherford, K. A., & McManus, K. J. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0747 · Cited by 89
Nano-PROTACs: state of the art and perspectives
Zhong, J., Zhao, R., Wang, Y., Su, Y., & Lan, X. (2024) · Nanoscale · doi:10.1039/d3nr06059d · Cited by 82
ClickRNA-PROTAC for Tumor-Selective Protein Degradation and Targeted Cancer Therapy
Teng, X., Zhao, X., Dai, Y., Zhang, X., Zhang, Q., Wu, Y., Hu, D., & Li, J. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c06402 · Cited by 72
Chen, S., Cui, J., Chen, H., Yu, B., & Long, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115911 · Cited by 74
Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives
Hu, J., Zhang, D., Tian, K., Ren, C., Li, H., Lin, C., Huang, X., Liu, J., Mao, W., & Zhang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115475 · Cited by 65
Zhao, L., Rao, X., Zheng, R., Huang, C., Kong, R., Cheng, H. B., Li, B., & Li, S. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c01812 · Cited by 69
Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Li, J., Chen, X., Lü, A., & Liang, C. (2023) · The Innovation · doi:10.1016/j.xinn.2023.100413 · Cited by 95
Teng, M., & Gray, N. S. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.06.020 · Cited by 66
Sang, R., Fan, R., Deng, A., Gou, J., Lin, R., Zhao, T., Hai, Y., Song, J., Liu, Y., Qi, B., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00118 · Cited by 62
Ru, Q., Li, Y., Zhang, F., Chen, L., Wu, Y., Min, J., & Wang, F. (2025) · Bone Research · doi:10.1038/s41413-024-00398-6 · Cited by 68
Self-citation2-Aminobenzothiazoles in anticancer drug design and discovery
Huang, G., Cierpicki, T., & Grembecka, J. E. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106477 · Cited by 68
Thomas, J. E., Wang, M., Jiang, W., Wang, M., Wang, L., Wen, B., Sun, D., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00492 · Cited by 61
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Mi, D., Li, Y., Gu, H., Li, Y., & Chen, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115444 · Cited by 59
Dutta, R., Devarajan, A., Talluri, A., Das, R., & Thayumanavan, S. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c00131 · Cited by 60
Park, B., Choi, J., Lee, J.-H., Kim, Y., Lee, W. J., Lee, A., Sun, I., Yoon, H. Y., Kim, Y., Kim, S. H., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02405-6 · Cited by 69
Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach
Chen, Q., Liu, C., Wang, W., Meng, X., Cheng, X., Li, X., Cai, L., Luo, L., He, X., Qu, H., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00797 · Cited by 55
PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer
Zhang, H., Zhang, L., He, Y., Jiang, D., Sun, J. L., Luo, Q., Liang, H., Wang, T., Li, F., Tang, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217112 · Cited by 57
Overcoming cancer therapy resistance: From drug innovation to therapeutics
Wei, J., Lu, M., Wei, T., Fleishman, J. S., Yu, H. J., Chen, X.-L., Kong, X.-T., Sun, S., Li, N., Yang, Y., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101229 · Cited by 59
Bai, Y., Yang, W., Hou, X., Shen, D., Zhang, S., Li, N., Qiao, Y.-Y., Wang, S., Yuan, S., & Liu, H. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115606 · Cited by 52
Homo-BacPROTAC-induced degradation of ClpC1 as a strategy against drug-resistant mycobacteria
Junk, L., Schmiedel, V. M., Guha, S., Fischel, K., Greb, P., Vill, K., Krisilia, V., van Geelen, L., Rumpel, K., Kaur, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46218-7 · Cited by 52
Leveraging aptamers for targeted protein degradation
Yang, Z., Pang, Q., Zhou, J., Xuan, C., & Xie, S. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.05.008 · Cited by 51
Jiang, X., Lai, Y., Xia, W., Yang, W., Wang, J., Pan, J., Zhao, Q., Zhou, X., Li, S., Zhang, S., et al. (2025) · Advanced Materials · doi:10.1002/adma.202411869 · Cited by 70
Bhole, R. P., Kute, P. R., Chikhale, R. V., Bonde, C. G., Pant, A., & Gurav, S. S. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106720 · Cited by 53
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Li, X., Liu, Q., Xie, X., Peng, C., Pang, Q., Liu, B., & Han, B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01712 · Cited by 46
Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
Wang, H., Zhou, R., Xu, F., Yang, K., Zheng, L., Zhao, P., Shi, G., Dai, L., Xu, C., Yu, L., et al. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00385-8 · Cited by 51
Zhang, Y., Gu, W., Chen, W., Zhu, J., Fan, L., Zhang, L., Zhao, L., & Miao, Q. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c18398 · Cited by 48
Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
Fan, G., Chen, S., Zhang, Q., Yu, N., Shen, Z., Liu, Z., Guo, W., Tang, Z., Yang, J., & Liu, M. (2025) · MedComm · doi:10.1002/mco2.70401 · Cited by 61
Chan, K., Sathyamurthi, P. S., Queisser, M. A., Mullin, M. J., Shrives, H. J., Coe, D. M., & Burley, G. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00366 · Cited by 46
Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy
Song, Y., Dong, Q., Ni, Y.-K., Xu, X., Chen, C.-X., & Chen, W. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s448684 · Cited by 51
The progress of molecules and strategies for the treatment of HBV infection
Pan, Y., Xia, H., He, Y., Zeng, S., Shen, Z., & Huang, W. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1128807 · Cited by 48
Recent advances in targeted protein degraders as potential therapeutic agents
Yang, N., Kong, B., Zhu, Z., Huang, F., Zhang, L., Lu, T., Chen, Y., Zhang, Y., & Jiang, Y. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10606-w · Cited by 45
Li, Z., Ren, G., Wang, X., Li, X., Ding, L., Zhu, J., Zhang, Y., Zhang, C., Zou, J., & Chen, X. S. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123387 · Cited by 45
Sato, T., Castro, C. D., Yoon, S.-H., Zhao, Y., Greenlee, W. J., Weber, P. C., Viswanathan, U., Kulp, J. L., Brooks, D. J., Demay, M. B., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214396119 · Cited by 43
Strategies for Precise Modulation of Protein Degradation
He, S., Dong, G., & Sheng, C. (2025) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5c00003 · Cited by 45
Yu, Y., Hu, W., Xu, Y., Xu, H.-B., & Gao, J.-Q. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113719 · Cited by 45
Repurposing AS1411 for constructing ANM-PROTACs
Fu, X., Li, J., Chen, X., Chen, H., Wang, Z., Qiu, F., Xie, D., Huang, J., Yue, S., Cao, C., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.03.011 · Cited by 42
Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution
Xiao, Y., Yuan, Y., Liu, Y., Lin, Z., Zheng, G., Zhou, D., & Lv, D. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00723 · Cited by 42
Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives
Li, J., Cai, Z., Li, X., & Zhuang, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01223 · Cited by 39
Kamaraj, R., Ghosh, S., Das, S., Sen, S., Kumar, P. R., Majumdar, M., Dasgupta, R., Mukherjee, S., Das, S., Ghose, I., et al. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00253 · Cited by 38
Tang, H., Wang, L., Wang, T., Yang, J., Zheng, S., Tong, J., Jiang, S., Zhang, X., & Zhang, K. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115607 · Cited by 37
TAC‐tics for Leveraging Proximity Biology in Drug Discovery
Nalawansha, D. A., Mangano, K., den Besten, W., & Potts, P. R. (2023) · ChemBioChem · doi:10.1002/cbic.202300712 · Cited by 38
Self-citationWang, F., Dong, G., Ding, M., Yu, N., Sheng, C., & Li, J. (2023) · Small · doi:10.1002/smll.202306378 · Cited by 43
Key Considerations in Targeted Protein Degradation Drug Discovery and Development
Qin, L., Dai, H., & Wang, J. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.934337 · Cited by 37
Discovery of Ligands for TRIM58, a Novel Tissue-Selective E3 Ligase
Hoegenauer, K., An, S., Axford, J., Benander, C., Bergsdorf, C., Botsch, J. J., Chau, S., Fernández, C. F., Gleim, S., Hassiepen, U., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00259 · Cited by 35
A comprehensive review of emerging approaches in machine learning for de novo PROTAC design
Gharbi, Y., & Mercado, R. (2024) · Digital Discovery · doi:10.1039/d4dd00177j · Cited by 38
Current strategies for improving limitations of proteolysis targeting chimeras
Pu, C., Wang, S., Liu, L., Feng, Z., Zhang, H., Gong, Q., Sun, Y., Guo, Y., & Li, R. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.107927 · Cited by 33
Shi, Y., Wang, A.-J., Liu, X., Dai, M., & Cai, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1193222 · Cited by 32
Tandem‐Activatable PROTAC Prodrug for Tumor Biomarker‐Driven Near‐Infrared Opto‐Proteolysis
Lu, X., Wang, X., Liao, H., Sha, B., Zhang, Y., & Li, J. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202510641 · Cited by 35
Liu, J., Ma, T., Yao, R., Li, L., Zheng, Q., & Wang, M. (2026) · Cell · doi:10.1016/j.cell.2025.12.007 · Cited by 33
PROTACs in the Management of Prostate Cancer
Poornachandra, Y., Babalghith, A. O., Andra, V. V., & Syed, R. (2023) · Molecules · doi:10.3390/molecules28093698 · Cited by 34
Zhu, H., Gao, F., Li, Y., Jiang, M., Zhang, Y., Chen, K., Han, L., Xue, S., Wang, K., Fan, Q., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102308 · Cited by 31
Sun, C., Liu, S., Lau, J. W., Yang, H., Chen, Y., & Xing, B. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202423057 · Cited by 34
Central Nervous System Targeted Protein Degraders
Thomas, B. A. I., Lewis, H. L., Jones, D. H., & Ward, S. E. (2023) · Biomolecules · doi:10.3390/biom13081164 · Cited by 30
Gan, X., Wang, F., Luo, J., Zhao, Y., Wang, Y., Yu, C., & Chen, J. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106624 · Cited by 29
Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment
Fan, L., Tong, W., Wei, A., & Mu, X. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133680 · Cited by 34
Autophagy mediated targeting degradation, a promising strategy in drug development
Zhang, J., Pan, X., Ji, W., & Zhou, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107466 · Cited by 28
Abbas, A., & Ye, F. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134293 · Cited by 31
Bao, Y., Xu, Z., Cheng, K., Li, X., Chen, F., Yuan, D., Zhang, F., Run-Yu, A., Zeng, X., Zhao, Y., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c17054 · Cited by 35
Recent advances in developing targeted protein degraders
Cheng, B., Li, H., Peng, X., Chen, J., Shao, C., & Kong, Z. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117212 · Cited by 32
Workflow for E3 Ligase Ligand Validation for PROTAC Development
Miletić, N., Weckesser, J., Mosler, T., Rathore, R., Hoffmann, M. E., Gehrtz, P., Schlesiger, S., Hartung, I. V., Berner, N., Wilhelm, S., et al. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.4c00812 · Cited by 28
Lin, J., Chen, Z., Zhang, D., Zhang, N., Chen, H., & Guo, D. (2025) · Macromolecular Rapid Communications · doi:10.1002/marc.202401051 · Cited by 31
Peptide-based PROTACs: Current Challenges and Future Perspectives
Wang, H., Chen, M., Zhang, X., Xie, S., Qin, J., & Li, J. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230130121822 · Cited by 29
Covalent PROTAC design method based on a sulfonyl pyridone probe
Luo, Q., Wang, Y., Hou, Z., Liang, H., Tu, L., Xing, Y., Wan, C., Liu, J., Wang, R. Y., Zhu, L., et al. (2023) · Chemical Communications · doi:10.1039/d3cc05127g · Cited by 28
Recent Progress in DNA Damage Response-Targeting PROTAC Degraders
Cheng, B., Fei, X., Ding, Z., Peng, X., Su, Z., Pan, W., & Chen, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00015 · Cited by 28
Wu, M., Wu, Y., Jin, Y., Mao, X., Zeng, S., Yu, H., Zhang, J., Jin, Y., Wu, Y., Xu, T., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00644 · Cited by 29
Lu, X., Jin, J., Wu, Y., Lin, J., Zhang, X., Lu, S., Zhang, J., Zhang, C., Ren, M., Chen, H., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.09.022 · Cited by 41
Shaik, S., Gayam, P. K. R., Chaudhary, M., Singh, G., & Pai, A. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107868 · Cited by 27
Hulse, M., Wang, M., Xu, C., Carter, J., Agarwal, A., Lu, L., Pitis, P., Bhagwat, N., Rager, J. D., Kurian, J. J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1141 · Cited by 34
CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications
Thapa, R., Bhat, A. A., Gupta, G., Jyothi, S. R., Kaur, I., Kumar, S., Sharma, N., Prasad, G. V. S., Pramanik, A., & Ali, H. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70009 · Cited by 28
Recent advances in dual PROTACs degrader strategies for disease treatment
Liu, J., Liu, Y., Tang, J., Gong, Q., Yan, G., Fan, H., Zhang, X., & Pu, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116901 · Cited by 25
Sun, J., Gu, M., Peng, L., Guo, J., Chen, P., Wen, Y., Fang, F., Chen, X., Liu, T., Chen, Y., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c11003 · Cited by 27
E3 ubiquitin ligases and their therapeutic potential in disease Management
Madhukar, G., Haque, M. A., Khan, S., Kim, J.-J., & Danishuddin (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116875 · Cited by 26
Discovery of a bifunctional PKMYT1-targeting PROTAC empowered by AI-generation
Wang, Y., Wang, X., Liu, T., Wang, C., Meng, Q., Meng, F., Yu, J., Liu, J., Fan, Y., Gennert, D. G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65796-8 · Cited by 32
Discovery of a selective TC-PTP degrader for cancer immunotherapy
Miao, J., Dong, J., Miao, Y., Bai, Y., Qu, Z., Jassim, B. A., Huang, B., Nguyen, Q. D., Ma, Y., Murray, A. A., et al. (2023) · Chemical Science · doi:10.1039/d3sc04541b · Cited by 25
Rational Proteolysis Targeting Chimera Design Driven by Molecular Modeling and Machine Learning
Tan, S., Chen, Z., Lu, R., Liu, H., & Yao, X. (2025) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.70013 · Cited by 26
Pan, M., Yang, C., Fu, Z., Yang, Y., Zhuo, Y., Hou, H., & Li, J. (2025) · Advanced Science · doi:10.1002/advs.202501384 · Cited by 27
The Peptide PROTAC Modality: A New Strategy for Drug Discovery
Zhu, Y., Dai, Y., & Tian, Y. (2025) · MedComm · doi:10.1002/mco2.70133 · Cited by 25
He, S., Huang, W., Zhu, Y., Gao, F., Fang, Y., Zhu, J., Bao, Y., Dong, G., & Sheng, C. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202511467 · Cited by 22
JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis
Wu, J., Li, L., Zhu, Q., Zhang, T., Miao, F., Cui, Z., Dong, G., Tai, Z., & Chen, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116167 · Cited by 25
Pt(IV)-PROTAC Complexes with Synergistic Antitumor Activity and Enhanced Membrane Permeability
Li, C.-X., Zou, Z.-R., Xu, S., Shi, J.-H., Zou, Y., Yan, M., & Zhang, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02909 · Cited by 20
Liu, Y., Zhang, X., Chen, X., & Zhang, F. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2025.123621 · Cited by 20
High‐Throughput Miniaturized Synthesis of PROTAC‐Like Molecules
Tian, Y., Seifermann, M., Bauer, L., Luchena, C., Wiedmann, J. J., Schmidt, S., Geisel, A., Afonin, S., Höpfner, J., Brehm, M., et al. (2024) · Small · doi:10.1002/smll.202307215 · Cited by 26
Application of PROTACs in target identification and validation
Liu, Y., Liang, J. Y., Zhu, R., Yang, Y., Wang, Y., Wei, W., Li, H., & Chen, L. (2024) · Acta Materia Medica · doi:10.15212/amm-2024-0010 · Cited by 33
Overview of PRMT1 modulators: Inhibitors and degraders
Wu, J., Li, D., & Wang, L. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116887 · Cited by 21
Lee, E. C. Y., Reichl, K. D., & Gopalsamy, A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2355258 · Cited by 19
Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes
Taylor, J. D., Barrett, N., Cuesta, S. M., Cassidy, K. B., Pachl, F., Dodgson, J., Patel, R. J., Eriksson, T. M., Riley, A., Burrell, M. R., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06803-4 · Cited by 20
Wilms, G., Schofield, K., Maddern, S., Foley, C., Shaw, Y., Smith, B. E., Basantes, L. E., Schwandt, K., Babendreyer, A., Chavez, T., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01130 · Cited by 19
Metadata
- Authors
- Guenette, R. G., Yang, S. W., Min, J., Pei, B., & Potts, P. R.
- Affiliations
- Amgen (United States) (US)
- Corresponding author
- Potts, Patrick Ryan
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2022
- Volume
- 51
- Issue
- 14
- Pages
- 5740-5756
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W4280616471
- Cited by
- 324
- References
- 133
- Citations by year
- 2026: 87 · 2025: 110 · 2024: 77 · 2023: 40 · 2022: 10
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Society Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- PROTACs, targeted protein degradation, tissue selectivity, E3 ubiquitin ligase, bifunctional molecules, linker optimization, undruggable proteins, small molecule drug discovery
- MeSH terms
- Ligands, Ubiquitin-Protein Ligases, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.